IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Trial details
- Registry ID
- NCT05742607
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy; Durvalumab; MEDI4736, IMFINZI; Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy; Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607 | Innate Pharma | Phase 2 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |